Navigation Links
Celltex Therapeutics Corporation Expands Laboratory Operations And Adds Depth To Its Management Team

HOUSTON, Aug. 2, 2012 /PRNewswire/ -- Celltex Therapeutics Corporation, a leader in regenerative medicine services, today announced the appointments of Andrea Ferrenz, Executive Vice President, Legal Counsel, and Jane Shen Young, Manufacturing Research Scientist. Ferrenz's primary responsibility will be overseeing operations, including compliance with federal and state regulatory agencies. Young's primary responsibility will be research and development of manufacturing processes and products in regenerative science.

"Celltex is a fast growing company. The additions of Andrea and Jane will enhance our capabilities as we continue to grow," said David Eller, Chief Executive Officer of Celltex. "At Celltex, we firmly believe in the great therapeutic potential for adult stem cells and we are committed to the highest quality banking and multiplication services for clients and physicians."

Ferrenz has more than 15 years of experience in regulatory compliance and litigation, with expertise in food, drug and health law. Prior to Celltex, Ferrenz was Principal Attorney at Emord & Associates, P.C., in Washington, D.C. There, she counseled both national and international clients in health products industries operating under the jurisdiction of the FDA and FTC. Early in her career, Ferrenz worked with the U.S. Department of Health and Human Services and Children's National Medical Center's Center for Cancer and Transplantation Biology. 

Ferrenz received her Bachelor's degree in biology from University of Mary Washington in Fredericksburg, Virginia, and her juris doctorate from George Washington University Law School in Washington, D.C.

"As a pioneer in stem cell banking, Celltex is paving the way for this new frontier," said Ferrenz. "I hope my background in health and FDA law will be an asset to Celltex and I look forward to helping Celltex grow while maintaining positive relationships with government regulators who work to ensure the safety of health products."

Young joins Celltex from Pharmaceutical Product Development, Inc. in Middleton, Wisconsin, where she served as Associate Research Scientist. Formerly an Internal physician in the Department of Medicine at Wang-Jiang-Shan Hospital in Zhejiang, China, and a Visiting Scientist and Ph.D. in molecular biology and biochemistry at the Lund University, Sweden, Young has expertise in cell biology, molecular genetics and biochemistry. She has also co-authored publications on the development and optimization of laboratory assays, and cell sort and flow cytometry analysis.

Young received her medical degree from Zhejiang University School of Medicine. Zhejiang, China.  She received her doctoral degree from Lund University, Faculty of Medicine in Sweden.

"Stem cell banking is cutting edge technology in a field that holds great potential," noted Young. "Quality and safety are tantamount to the growth of this industry and I am excited to help Celltex provide stem cell banking and multiplication of the highest quality to its clients."

For more information on Celltex Therapeutics Corporation and its staff please visit

About Celltex

Celltex Therapeutics Corporation is a leader in providing services for the rapidly expanding field of regenerative medicine. Specifically, Celltex purifies, multiplies, and stores adult adipose-derived mesenchymal stem cells and rigorously follows the standards of good manufacturing practices for human cell laboratories. Celltex's laboratory currently holds more than fourteen patents protecting methodology and quality control. The Celltex process ensures extracted adult stem cells are separated, multiplied and stored without any genetic alteration or exposure to chemicals and drugs.  Celltex is currently researching new methods and technology for banking and stem cell treatment therapies to further the field of regenerative medicine and document the therapeutic impact of adult stem cell therapies on various medical conditions.

For more information contact:
Celltex at 713.590.1000

SOURCE Celltex Therapeutics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
2. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 1
3. United Therapeutics Corporation Reports Second Quarter 2012 Financial Results
4. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
5. United Therapeutics Corporation to Announce Second Quarter 2012 Financial Results Before Market Open on Thursday, July 26, 2012
6. Juventas Therapeutics Raises $22.2 Million Series B Financing
7. Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
8. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
9. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
10. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
11. United Therapeutics Announces Additional $100 Million Share Repurchase Program
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division of ... and optimized exclusively for Okuma CNC machining centers at The International Manufacturing Technology ... among several companies with expertise in toolholding, cutting tools, machining dynamics and distribution, ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: ) The ... enhanced security to access and transact across channels. ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
Breaking Biology News(10 mins):